Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of clear cell renal cell carcinoma~  * Metastatic disease~ * Primary tumor is considered amenable to surgery~* Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as \> 20 mm by conventional techniques or as \> 10 mm by spiral CT scan~* No untreated brain metastases~  * Treated brain metastases allowed provided lesion has been stable on two consecutive CT or MRI scans separated by ≥ 2 months~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Leukocytes ≥ 3,000/μL~* ANC ≥ 1,500/μL~* Platelet count ≥ 75,000/μL~* Hemoglobin ≥ 8.5 g/dL~* Total Bilirubin ≤ 2 times upper limits of normal (ULN)~* AST and ALT ≤ 2.5 times ULN~* Creatinine ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to undergo nephrectomy and treatment with sunitinib malate~* No history of allergic reactions attributed to compounds of similar chemical or biological composition to sunitinib malate~* No uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness/social situations that would limit compliance with study requirements~PRIOR CONCURRENT THERAPY:~* No prior systemic treatment with sunitinib malate~* No other concurrent investigational agents~* No concurrent combination antiretroviral therapy for HIV-positive patients~* Concurrent medications or substances known to affect, or with the potential to affect, the activity or pharmacokinetics of sunitinib malate allowed at the discretion of the principal investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Sunitinib (Type: EXPERIMENTAL): Sunitinib will be administered for 8 weeks prior to sugery

Based on this trial design, predict the completion outcome and termination type (if applicable).